SCHEMBL3015783

SCHEMBL3015783

Cc1ccc(C)c(-c2csc(N3CCC(S(=O)(=O)c4ccc(F)c(Cl)c4)CC3)n2)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AR P10275 8/20 0.53
NFKB1 P19838 2/20 0.41
NFKB2 Q00653 2/20 0.41
RELA Q04206 2/20 0.41
SMN1; SMN2 Q16637 5/20 0.40
ALDH1A1 P00352 2/20 0.40
MAPT P10636 2/20 0.40
CYP1A2 P05177 1/20 0.40
POLB P06746 1/20 0.40
CYP2C9 P11712 1/20 0.40
HPGD P15428 1/20 0.40
CYP2C19 P33261 1/20 0.40
HTT P42858 1/20 0.40
KMT2A Q03164 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
RAB9A P51151 3/20 0.39
NPC1 O15118 2/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
RAF1 P04049 1/20 0.37
BRAF P15056 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3008446 0.92 AR (0.55) ARNFKB1NFKB2RELASMN1; SMN2
SCHEMBL3019555 0.90 SMN1; SMN2 (0.46) ARSMN1; SMN2ALDH1A1MAPTCYP1A2
SCHEMBL3013940 0.90 AR (0.57) ARNFKB1NFKB2RELASMN1; SMN2
SCHEMBL3018857 0.89 AR (0.58) ARNFKB1NFKB2RELASMN1; SMN2
SCHEMBL3017092 0.88 SMN1; SMN2 (0.52) ARSMN1; SMN2ALDH1A1MAPTCYP1A2
SCHEMBL3017324 0.88 AR (0.57) ARNFKB1NFKB2RELASMN1; SMN2
SCHEMBL3017165 0.88 AR (0.61) ARNFKB1NFKB2RELASMN1; SMN2
SCHEMBL3017177 0.87 AR (0.54) ARNFKB1NFKB2RELASMN1; SMN2
SCHEMBL3019052 0.87 SMN1; SMN2 (0.40) ARSMN1; SMN2ALDH1A1MAPTCYP1A2
SCHEMBL3017995 0.87 AR (0.44) ARSMN1; SMN2ALDH1A1MAPTCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA AR 3801/4885NFKB1 1767/4885NFKB2 2341/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.